Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc.'s mission is to empower precision medicine at the local level. The company’s proprietary HTG EdgeSeq technology automates multiplexed molecular profiling of nucleic acids in a wide variety of solid and liquid samples, even when very limited in amount. The extraction free workflow paired with detection by next-generation sequencing offers many advantages and enables meaningful applications, such as identifying biomarkers important for precision medicine, understanding the clinical relevance of these biomarkers, and, ultimately, identifying treatment options.

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Molecular Diagnostics Announces Preliminary 2019 Unaudited Financial Results
Preliminary full year 2019 unaudited revenue of $19.2 million Cash and cash equivalents of $33.0 million as of December 31, 2019 TUCSON, Ariz. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision
Toggle Summary HTG Molecular Diagnostics to Host Key Opinion Leader Meeting on the Future of Precision Medicine
TUCSON, Ariz. , Dec. 03, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it will host a Key Opinion Leader (KOL) luncheon at 12:00 pm ET on Friday, December 13 th in Boston,
Toggle Summary HTG Molecular Diagnostics Expands Analytics Capabilities with Release of New Software Update
HTG EdgeSeq Reveal software version 2.0.0 streamlines data analysis process and enhances user experience TUCSON, Ariz. , Nov. 19, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, yesterday
Toggle Summary HTG Molecular Diagnostics Reports Third Quarter 2019 Results
 Product and product-related services revenue increased by 228% and 125% in the three and nine-month periods, respectively, compared to the prior year periods Call scheduled for today, November 12 , at 4:30pm ET TUCSON, Ariz. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc.
Toggle Summary HTG Molecular Diagnostics to Announce Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 12
TUCSON, Ariz. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will report its financial results for the third quarter ended September 30, 2019 after the market close on

Stock Chart

SEC Filings

Filing date Description

Securities offered to employees pursuant to employee benefit plans

Report of unscheduled material events or corporate event

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities